Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort

Department of Community Medicine 8 Health Care, University of Connecticut Health Center, Farmington, CT, 06030.
International Journal of Cancer (Impact Factor: 5.01). 04/2014; 134(8). DOI: 10.1002/ijc.28504
Source: PubMed

ABSTRACT Several prospective studies suggest that C-Reactive Protein (CRP), a non-specific serologic marker of inflammation, might be linked to risk of colorectal cancer (CRC) whereas others have reported null or protective effects. We analyzed data from 7,072 participants (50yrs-85yrs) in the U.S. National Health and Nutrition Examination Survey III (1988-94), a nationally representative cohort (n=33,994; 2m-85 yrs) with vital status follow-up to 2000. Hazard Ratios (HR) for mortality associated with baseline Clinically-Raised (≥ 1.00 mg/dL) and Intermediate (≥ 0.22 to 0.99 mg/dL) CRP levels were estimated using Cox Proportional Hazards Regression controlling for CRC risk factors. There were 59 deaths from CRC, 106 from Other Obesity-Related Cancers (Other-ORC), 1130 from Cardiovascular Disease (CVD). Participants with Clinically-Raised CRP at baseline were found to have a statistically significant greater risk of CRC death (HRs=2.36 to 2.47) in comparison to persons with undetected levels. HRs were lower for death from Other-ORC and CVD (1.82, 95% CI 1.05-3.15; 1.53, 95% CI 1.29-1.81; respectively). Intermediate CRP level was associated with a non-significant 10% to 21% increased risk for CRC death. HR for CRC death was higher among persons with a normal BMI (2.16, 95% 0.96-4.87, P=0.06) compared to those who were overweight (1.22, 95% CI 0.53-2.78) or obese (1.23, 95% CI, 0.37-4.08). A similar pattern was observed for Waist Circumference. This effect modification suggests that the impact of chronic inflammation may be independent of excess body fat. Future research is recommended to confirm emerging data that elevated serologic CRP might reflect underlying colonic inflammation. © 2013 Wiley Periodicals, Inc.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: C-reactive protein (CRP) is involved in a wide range of diseases. It is a powerful marker for inflammatory processes used for diagnostic and monitoring purposes. We aimed to establish reference values as data on the distribution of serum CRP levels in young European children are scarce.
    International journal of obesity (2005) 09/2014; 38 Suppl 2:S26-31. DOI:10.1038/ijo.2014.132 · 5.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Prolong inflammation is a central process observed in several chronic conditions and may be responsible for survival. There is an increasing evidence showing the role of diet in inflammation and habitual diet may be responsible for low-grade inflammation. The purpose of our study was to assess the effect of inflammatory properties of habitual diet measured by the Dietary Inflammatory Index (DII) on survival among surgical patients treated for colorectal cancer (CRC). Methods A follow-up study among 689 CRC patients (mean age 58 years, ±8.9; 56.7 % males) treated surgically was performed in Krakow, Poland. Habitual diet was assessed by a standardized semiquantitative food frequency questionnaire. Next, 23 dietary items were used to calculate DIIs. Vital records were verified to determine status of the participants. Results Study has shown linear association between DII and survival time among CRC patients with totally removed cancer treated by chemotherapy (b = −0.13, p = 0.024). After adjustment for several important covariates, DII was associated with survival during up to 3 years after surgery, but only in patients without distant metastases (3-year HRDII>−2.27 = 0.61, 95 % CI 0.38–0.99). Conclusions The results of the investigation have shown the usefulness of the DII as a potential predictor of survival among patients without distant metastases treated surgically for CRC.
    Journal of Cancer Research and Clinical Oncology 05/2014; 140(9). DOI:10.1007/s00432-014-1711-6 · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the impact of HAART-induced HIV suppression on levels of 24 serological biomarkers of inflammation and immune activation. A prospective cohort study. Biomarkers were measured with multiplex assays in centralized laboratories using stored serum samples contributed by 1697 men during 8903 person-visits in the Multicenter AIDS Cohort Study (MACS) from 1984 to 2009. Using generalized gamma models, we compared biomarker values across three groups, adjusting for possible confounders: HIV-uninfected (NEG); HIV-positive, HAART-naive (NAI); and HAART-exposed with HIV RNA suppressed to less than 50 copies/ml plasma (SUP). We also estimated changes in biomarker levels associated with duration of HIV suppression, using splined generalized gamma regression with a knot at 1 year. Most biomarkers were relatively normalized in the SUP group relative to the NAI group; however, 12 biomarkers in the SUP group were distinct (P < 0.002) from NEG values: CXCL10, C-reactive protein (CRP), sCD14, sTNFR2, tumour necrosis factor-alpha (TNF-α), sCD27, sGP130, interleukin (IL)-8, CCL13, BAFF, GM-CSF and IL-12p70. Thirteen biomarkers exhibited significant changes in the first year after viral suppression, but none changed significantly after that time. Biomarkers of inflammation and immune activation moved towards HIV-negative levels within the first year after HAART-induced HIV suppression. Although several markers of T-cell activation returned to levels present in HIV-negative men, residual immune activation, particularly monocyte/macrophage activation, was present. This residual immune activation may represent a therapeutic target to improve the prognosis of HIV-infected individuals receiving HAART.
    AIDS (London, England) 02/2015; 29(4):463-71. DOI:10.1097/QAD.0000000000000545 · 6.56 Impact Factor